(Q33412734)

English

Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

11

object named as

Dario Neri

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Secondo Lastoria

object named as

Secondo Lastoria

13

0 references

author name string

Luigi Aloj

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Laura D'Ambrosio

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michela Aurilio

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Anna Morisco

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ferdinando Frigeri

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Corradina Caraco'

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Francesca Di Gennaro

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gaetana Capobianco

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Leonardo Giovannoni

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hans D Menssen

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Antonio Pinto

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

17 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

867-877

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s00259-013-2658-6

0 references

Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

How I treat relapsed and refractory Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Treatment of newly diagnosed advanced stage Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Managing relapsed and refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Radioimmunotherapy in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

131I-tositumomab therapy as initial treatment for follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Design, construction, and characterization of a large synthetic human antibody phage display library

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radioimmunoconjugate

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Does rituximab have a place in treating classic hodgkin lymphoma?

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Comprehensive identification of proteins in Hodgkin lymphoma-derived Reed-Sternberg cells by LC-MS/MS.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Novel small-molecule therapy of Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2658-6

21 January 2018

Tenascin in Reactive Lymph Nodes and in Malignant Lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/24435772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues

1 reference

https://pubmed.ncbi.nlm.nih.gov/24435772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine

1 reference

https://pubmed.ncbi.nlm.nih.gov/24435772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bone marrow dosimetry for radioimmunotherapy: theoretical considerations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24435772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Connective tissue growth factor is expressed in malignant cells of Hodgkin lymphoma but not in other mature B-cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/24435772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature

1 reference

https://pubmed.ncbi.nlm.nih.gov/24435772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of angiogenesis in tumor growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/24435772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates

1 reference

https://pubmed.ncbi.nlm.nih.gov/24435772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absolute organ activity estimated by five different methods of background correction.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24435772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-013-2658-6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33412734&oldid=1975053148"